Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Part A: To evaluate the safety of HuMax-CD20 in patients with active rheumatoid arthritis. Part B: To evaluate the efficacy of HuMax-CD20 in patients with active rheumatoid arthritis using the American College of Rheumatology (ACR) Response Assessment and Disease Activity Score (DAS) at 12 to 24 weeks after initiation of treatment.
Critère d'inclusion
- active rheumatoid arthritis